Phase 2 Myeloma Trial, Recruiting NCT03271632 Sponsor: Shenzhen Geno-Immune Medical Institute Condition: Myeloma
Back to Myeloma

Phase 2 Myeloma Trial, Recruiting

NCT03271632
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been diagnosed with multiple myeloma (a type of blood cancer) confirmed by a specific protein marker, and there are no longer any treatment options available to cure it (including stem cell transplants).
  • You have not been able to reach complete remission (where no cancer is detected) after trying at least 4 different combination treatment plans.
  • Your cancer has come back a second or third time, you are in remission, but you cannot receive a donor stem cell transplant due to your age, other health conditions, or no matching donor being available.
  • Your cancer came back less than 1 year after your last chemotherapy treatment ended.
  • Your cancer came back or is still present after a previous stem cell transplant (using your own or a donor's cells), you have had at least 1 other treatment, and you are not able to have a donor stem cell transplant.
  • You still have signs of cancer remaining after your first round of treatment and are not eligible for a stem cell transplant using your own cells.
  • Your doctor expects you to live for more than 12 weeks.
  • Your kidney function is within an acceptable range (confirm with trial site).
  • Your liver enzyme levels are within an acceptable range (confirm with trial site).
  • Your bilirubin (a liver-related substance in your blood) is at an acceptable level (confirm with trial site).
  • If your cancer has come back after any stem cell transplant, you may be eligible regardless of what other treatments you have had.
  • You have suitable veins to allow a blood-collection procedure called apheresis, and no health reasons that would prevent it.
  • You are willing and able to give your informed consent to participate.

Who may not be able to join:

  • You are pregnant or currently breastfeeding.
  • You have an active infection that is not under control.
  • You have an active hepatitis B or hepatitis C infection.
  • You are currently taking steroid medications by mouth or injection (note: steroid inhalers are generally allowed).
  • You have previously received a related type of gene-modified immune cell therapy called CAR-T cell therapy targeting the same area.
  • You have any other serious medical condition that is not under control and would make it unsafe to participate (confirm with trial site).
  • You are living with HIV.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Lung-Ji Chang, Shenzhen Geno-Immune Medical Institute

Phone: +86 0755-86573763

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Shenzhen Geno-Immune Medical Institute
Registry
ClinicalTrials.gov
Start date
1 June 2026
Est. completion
31 December 2029

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Percentage of patients with treatment related adverse effect

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov